Biotech | May 16, 2022
Antengene announces commercial availability of Xpovio in China
The drug will be available in 600 hospitals and 105 DTPs
The drug will be available in 600 hospitals and 105 DTPs
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
In clinical trials, treatment proved more effective than other therapies evaluated
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
India has the second-largest number of adults with diabetes globally, after China
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Subscribe To Our Newsletter & Stay Updated
